MétaCan
Menu
Back to cohort
Record W2565306870 · doi:10.1093/neuonc/now212.202

DDIS-11. MOLECULAR MECHANISMS OF DIANHYDROGALACTITOL (VAL-083) IN OVERCOMING CHEMO-RESISTANCE IN GLIOBLASTOMA

2016· article· en· W2565306870 on OpenAlexaff
Beibei Zhai, Anna Golebiewska, Anne Steinø, Jeffrey Bacha, Dennis Brown, Simone P. Niclou, Mads Daugaard

Bibliographic record

VenueNeuro-Oncology · 2016
Typearticle
Languageen
FieldMaterials Science
TopicNanoparticle-Based Drug Delivery
Canadian institutionsDelmar (Canada)University of British Columbia
Fundersnot available
KeywordsTemozolomideCancer researchDNA repairBevacizumabMedicineCell cycleDNA damageMethyltransferaseCancerGliomaChemotherapyBiologyInternal medicineDNAMethylationGenetics

Abstract

fetched live from OpenAlex

Glioblastoma (GBM) is the most aggressive malignant brain cancer. The heterogeneous nature of GBM tumors and highly chemoresistant cancer stem-cells (CSCs) comprise significant clinical challenges. Most GBM tumors express O6-methylguanine-DNA-methyltransferase (MGMT) causing intrinsic chemoresistance to temozolomide and CCNU. Even tumors initially responsive to temozolomide, often recur with deficient DNA mismatch repair system (MMR) leading to acquired chemoresistance to temozolomide. Alteration in p53, particularly gain-of-function mutations, are correlated with poor prognoses in GBM, potentially by increasing MGMT-expression and temozolomide-resistance. Second-line treatment with bevacizumab, while successfully inducing intra-tumor hypoxia, has not improved overall survival. This is possibly due to GBM CSCs rapidly adapting to hypoxia by upregulating glucose-uptake and increasing invasiveness. Dianhydrogalactitol (VAL-083) is a bi-functional alkylating agent that readily crosses the blood-brain barrier, accumulates in brain tumor tissue and has demonstrated activity against GBM in prior NCI-sponsored clinical trials. VAL-083 induces interstrand cross-links at guanine-N7 causing DNA double-strand breaks and cell-death. VAL-083 is equally active against GBM CSCs and non-CSCs, and the activity is MGMT-independent and appears minimally dependent on wild-type p53, in vitro. A Phase I/II clinical trial studying VAL-083 in recurrent GBM, after temozolomide and bevacizumab failure, suggested potential of VAL-083 to offer clinically meaningful survival benefits. Here we report a distinct mechanism-of-action of VAL-083, showing that VAL-083 leads to irreversible S-phase cell-cycle arrest, activation of the homologous recombination pathway and ensuing cell-death, through mechanisms independent of MGMT and MMR. We used biochemical and microscopic analyses of DNA repair markers to investigate the VAL-083-induced DNA damage response in cancer-cells harbouring wild-type or mutated MMR-proteins and p53. We furthermore investigated the cytotoxic activity of VAL-083 against GBM cancer-cells under normoxia vs. hypoxia. Our results demonstrate a distinct anti-cancer mechanism for VAL-083. At the meeting we will present further results clarifying VAL-083’s potential to overcome chemoresistance in the treatment of GBM.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.246
Teacher spread0.238 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicNanoparticle-Based Drug DeliveryFrench-language works237,207